Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Cyclopentanohydrophenanthrene ring system doai
Patent
1994-09-02
1996-12-10
Jordan, Kimberly
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Cyclopentanohydrophenanthrene ring system doai
514255, 514256, 514277, 514299, 514300, 514361, 514362, 514363, 514364, 514372, 514374, 514378, 514381, 514383, 514384, 514393, 514394, 514396, 514401, 514469, 514843, A61K 3156, A61K 31495, A61K 31505, A61K 31435, A61K 3144, A61K 3141, A61K 31425, A61K 3142, A61K 31415, A61K 3134
Patent
active
055831281
ABSTRACT:
The invention relates to the use of aromatase inhibitors for contraception in female primates and to a method for contraception in female primates using such substances and to the use of those substances for the preparation of pharmaceutical compositions for contraception in female primates.
REFERENCES:
patent: 4289762 (1981-09-01), Metcalf et al.
patent: 4322416 (1982-03-01), Metcalf et al.
patent: 4617307 (1986-10-01), Browne
patent: 4677129 (1987-06-01), Alder et al.
patent: 4728645 (1988-03-01), Browne
patent: 4749713 (1988-06-01), Bowman et al.
patent: 4808616 (1989-02-01), Buzzetti
patent: 4839379 (1989-06-01), Stanek et al.
patent: 4857660 (1989-08-01), Alder et al.
patent: 4889861 (1989-12-01), Browne
patent: 4904650 (1990-02-01), Buzzetti et al.
patent: 4910212 (1990-03-01), Boyle et al.
patent: 4937250 (1990-06-01), Bowman et al.
patent: 4978672 (1990-12-01), Bowman et al.
patent: 5002940 (1991-03-01), Geller et al.
patent: 5057521 (1991-10-01), Hausler et al.
patent: 5071861 (1991-12-01), Bowman et al.
patent: 5073574 (1991-12-01), Lang
patent: 5098911 (1992-03-01), Ibrahim
patent: 5112845 (1992-06-01), Bowman et al.
patent: 5352795 (1994-10-01), Bowman et al.
Brodie et al.; J. Steroid Biochemistry, 11, 107-112 (1979) "Aromatase Inhibitors and Their Use in Controlling Estrogen Dependent Processes".
Wu et al; J. Reprod. Fert. 66, 655-662 (1982) "Effect of Aromatase Inhibitor on Estrogen Production in Rabbit Blastocytes".
Steele et al; Steroids 50, 147-161 (1986) "In Vitro & In Vivo Studies Demonstrating Potent and Selective Estrogen Inhibition with the non-steroidal Aromatase Inhibitor CGS16949A."
Mead et al; Biology of Reproduction 27, 540-547 (1982). "Is Estrogen Required for Implantation in the Ferret."
Brodie et al; Endocrinology 104, No. 1, 118-121 (1979) "Antifertility Effects of an Aromatase Inhibitor, 1,4,6-Androstatriene-3,17-Dione".
Brodie et al; Biology of Reproduction. 18, 365-370 (1978). "Aromatase Inhibitors III. Studies on the Antifertility Effect of 4-Acetoxy-4-Androstene-3,17-Dione."
Brodie et al; Endocrinology 100: 1684-1695. "The Effect of an Aromatase Inhibitor, 4-hydroxy-4-Androstene-3,17-Dione on Estrogen Dependent Processes in Reproduction and Brest Cancer." (1975).
Mead et al. Biology of Reproduction 22, 560-565 (1980) "Aromatase Activity in the Corpora Lutea of the Ferret."
Moudgal et al; Biology of Reproduction 1991 (Abstract) "Contraceptive Efficacy of an Aromatase Inhibitor (CGS 16949A) as analyzed in the Bonnet Monkey."
Gosh et al; Biology of Reproduction 40, Suppl. 1, 122. "Effect of an Aromatase Inhibitor (4-hydroxyandrostenedione) in Pre-Implantation Hamster Embryos" (1989).
Derwent Abstract of EP 277910; Aug. 1988.
Ciba-Geigy Corporation
Fishman Irving M.
Jordan Kimberly
Kaiser Karen G.
Mathias Marla J.
LandOfFree
Contraception in female primates without affecting the menstrual does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Contraception in female primates without affecting the menstrual, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Contraception in female primates without affecting the menstrual will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-424330